Abstract:AIM:To observe the clinical effect of conbercept to improve visual acuity of patients with wet age-related macular degeneration(wAMD).
METHODS:Seventy patients(70 eyes)with wAMD were selected and divided into study group and control group according to different therapies. The control group received intravitreal injection of triamcinolone acetonide. The study group adopted the intravitreal injection with conbercept. Uncorrected visual acuity, the score of reading ability, the central macular thickness(CMT)and the macular pigment optical density of two groups before and after treatment was observed.
RESULTS: the visual acuity of study group was 0.47±0.11 and 0.60±0.14 respectively at 6mo and 1a after treatments, those of control group were 0.27±0.09 and 0.30±0.15. The differences between the two groups at the two points were statistically significant(P<0.05). The CMT of study group was 336.8±65.4 and 301.5±76.8μm respectively at 6mo and 1a after treatments, those of control group were 379.4±88.2 and 368.6±81.3μm. The differences between the two groups at the two points were statistically significant(P<0.05). The macular pigment optical density of study group was 0.19±0.07 and 0.25±0.09DU respectively at 6mo and 1a after treatments, those of control group were 0.12±0.05 and 0.14±0.05μm. The differences between the two groups at the two points were statistically significant(P<0.05).
CONCLUSION:The intravitreal injection with conbercept has a favorable clinical effect on the treatment of wAMD, Which can greatly improve the uncorrected visual acuity and is worthy promotion.
